MedPath
HSA Product

IMOVAX POLIO INJECTION

Product approved by Health Sciences Authority (SG)

Basic Information

IMOVAX POLIO INJECTION

INJECTION

Regulatory Information

SIN10608P

January 6, 1999

Prescription Only

Therapeutic

SUBCUTANEOUS, INTRAMUSCULAR

August 10, 2023

May 30, 2025

XJ07BF03

Company Information

SANOFI PASTEUR

SANOFI-AVENTIS SINGAPORE PTE. LTD.

SANOFI-AVENTIS SINGAPORE PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**Contraindications** Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_, or to any vaccine containing the same substances, to neomycin, streptomycin or polymyxin B. Common transient contraindications to any vaccination: in case of fever or acute illness, it is best to postpone vaccination.

Indication Information

**Therapeutic indications** This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccination. IMOVAX POLIO must be used according to effective official recommendations.

© Copyright 2025. All Rights Reserved by MedPath